Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
405
¥ millionWording
Conditional
How definitive the wording is.This transaction
Acquisition of shares (making the company a subsidiary)CounterpartyOkazaki Yoshinori (岡﨑善憲)
Disclosing companyElitz Holdings Co.,Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
Building and condominium maintenance business
Location Shimogyo-ku, Kyoto CityShare capital ¥30 millionDate of incorporation 30 November 1978
Net Sales¥1,453 million (fiscal year ended May 2025)
Operating profit¥20 million (fiscal year ended May 2025)
Net income for the current fiscal year¥13 million (fiscal year ended May 2025)
Net assets¥434 million (fiscal year ended May 2025)
Consideration and expenses
Acquisition priceCommon shares of 株式会社共栄薬研 (approximate amount): ¥400 million
Expenses other than the acquisition priceAdvisory fees and other expenses (approximate amount): ¥5 million
Impact on Business Performance
The impact on the consolidated earnings forecast will be immaterial, and no revision to the consolidated earnings forecast will be made.
| Item | Details |
|---|---|
| Transaction name | Acquisition of shares (making the company a subsidiary) |
| Counterparty name | Okazaki Yoshinori (岡﨑善憲) |
| Name of the Subject Company | 株式会社共栄薬研 (including its wholly owned subsidiary 株式会社ライフライン) |
| Business Description of the Subject Company | Building and condominium maintenance business |
| Location of the Subject Company | Shimogyo-ku, Kyoto City |
| Capital Stock of the Subject Company | ¥30 million |
| Date of Establishment of the Subject Company | 30 November 1978 |
| Net Sales of the Subject Company | ¥1,453 million (fiscal year ended May 2025) |
| Operating Profit of the Subject Company | ¥20 million (fiscal year ended May 2025) |
| Net Income of the Subject Company | ¥13 million (fiscal year ended May 2025) |
| Net Assets of the Subject Company | ¥434 million (fiscal year ended May 2025) |
| Acquisition price | Common shares of 株式会社共栄薬研 (approximate amount): ¥400 million |
| Expenses other than the acquisition price | Advisory fees and other expenses (approximate amount): ¥5 million |
| Number of shares acquired | 73,980 shares (number of voting rights: 73,980) |
| Voting rights ownership percentage | Before －％ → after 100.0％ |
| Impact on Business Performance | The impact on the consolidated earnings forecast will be immaterial, and no revision to the consolidated earnings forecast will be made. |
| Date of board resolution | 11 June 2026 |
| Contract Date | 15 June 2026 |
| Execution Date / Effective Date | 31 July 2026 (planned) |
Items this document does not state (13)
Type of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Valuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company expects synergies by strengthening its real estate management business structure, developing customers for both companies, converting properties owned by the target company's customers into managed properties, and reducing costs by bringing maintenance and other services in-house.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.